Canadian Institute for Health Information. Organ replacement in Canada: CORR annual statistics 2013–2022. Published 2023. Available from: https://www.cihi.ca/en/organ-replacement-in-canada-corr-annual-statistics. Accessed 11 July 2024.
Bello AK, Ronksley PE, Tangri N, Kurzawa J, Osman MA, Singer A, Grill A, Nitsch D, Queenan JA, Wick J, Lindeman C, Soos B, Tuot DS, Shojai S, Brimble S, Mangin D, Drummond N. Prevalence and demographics of CKD in Canadian primary care practices: A Cross-sectional Study. Kidney Int Rep. 2019;4(4):561–70.
Secora A, Alexander GC, Ballew SH, et al. Kidney function, polypharmacy, and potentially inappropriate medication use in a community-based cohort of older adults. Drugs Aging. 2018;35(8):735–50.
Lea-Henry TN, Carland JE, Stocker SL, Coresh J, Grams ME. Clinical pharmacokinetics in kidney disease: Fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085–95.
Laville SM, Gras-Champel V, Moragny J, Metzger M, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Robinson BM, Stengel B, Massy ZA, Liabeuf S, Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Group. Adverse drug reactions in patients with CKD. Clin J Am Soc Nephrol. 2020;15(8):1090–102.
Okpechi IG, Tinwala MM, Muneer S, Zaidi D, Ye F, Hamonic LN, Khan M, Sultana N, Brimble S, Grill A, Klarenbach S, Lindeman C, Molnar A, Nitsch D, Ronksley P, Shojai S, Soos B, Tangri N, Thompson S, Tuot D, Drummond N, Mangin D, Bello AK. Prevalence of polypharmacy and associated adverse health outcomes in adult patients with chronic kidney disease: protocol for a systematic review and meta-analysis. Syst Rev. 2021;10:198.
Quintana-Bárcena P, Lord A, Lizotte A, Berbiche D, Lalonde L. Prevalence and management of drug-related problems in chronic kidney disease patients by severity level: A subanalysis of a cluster randomized controlled trial in community pharmacies. J Manag Care Spec Pharm. 2018;24(2):173–81.
MacRae C, Mercer S, Guthrie B. Potentially inappropriate primary care prescribing in people with chronic kidney disease: a cross-sectional analysis o f a large population cohort. Br J Gen Pract. 2021;71(708):e483–90.
Ruiz-Boy S, Rodriguez-Reyes M, Clos-Soldevila J, Rovira-Illamola M. Appropriateness of drug prescriptions in patients with chronic kidney disease in primary care: a double-center retrospective study. BMC Prim Care. 2022;23(1):323.
Laville SM, Metzger M, Stengel B, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Ayav C, Speyer E, Robinson BM, Massy ZA, Liabeuf S, Chronic Kidney Disease-Renal Epidemiology and Information Network (CKD-REIN) Study Collaborators. Evaluation of the adequacy of drug prescriptions in patients with chronic kidney disease: results from the CKD-REIN cohort. Br J Clin Pharmacol. 2018;84(12):2811–23.
Tesfaye WH, Castelino RL, Wimmer BC, Zaidi STR. Inappropriate prescribing in chronic kidney disease: A systematic review of prevalence, associated clinical outcomes and impact of interventions. Int J Clin Pract. 2017;71(7):10.
By the 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052–2081.
Laville SM, Gras-Champel V, Hamroun A, Moragny J, Lambert O, Metzger M, Jacquelinet C, Combe C, Fouque D, Laville M, Frimat L, Robinson BM, Bieber B, Stengel B, De Pinho Alencar N, Massy ZA, Liabeuf S, CKD-REIN Study Group. Kidney function decline and serious adverse drug reactions in patients with CKD. Am J Kidney Dis. 2024;83(5):601–14.
Desrochers JF, Lemieux JP, Morin-Bélanger C, Paradis FS, Lord A, Bell R, Berbiche D, Bárcena PQ, Séguin NC, Desforges K, Legris MÈ, Sauvé P, Lalonde L. Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. Am J Kidney Dis. 2011;58(4):527–35.
Tran J, Shaffelburg C, Phelan E, Neville H, Lively A, Poyah P, Tennankore K, More K, Soroka S, Harpell D, Wilson JA. Community pharmacists’ perspectives on assessing kidney function and medication dosing for patients with advanced chronic kidney disease: A qualitative study using the theoretical domains framework. Can Pharm J. 2023;156(5):272–81.
Taji L, Battistella M, Grill AK, Cunningham J, Hemmelgarn BL, Quinn KM, Thomas A, Brimble KS. Medications used routinely in primary care to be dose-adjusted or avoided in people with chronic kidney disease: Results of a modified Delphi study. Ann Pharmacother. 2020;54(7):625–32.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Meth. 2005;8(1):19–32.
Levac D, Colquhoun H, O’Brien KK. Scoping studies: Advancing the methodology. Implement Sci. 2010;5:69.
Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, O’Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ, Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L, Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV, Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467–73.
Peters M, Casey M, Tricco A, Pollock D, Munn Z, Alexander L, McInerney P, Godfrey CM, Khalil H. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020;18(10):2119–26.
Wilson J, Halliday K, Battistella M, Wazny L, Marin J, Pitman J, Naylor H, Gillis L. High-risk medications commonly used in individuals with chronic kidney disease across primary care settings. Charlottesville, VA: Open Science Framework. Available from:
https://osf.io/b7jxu. Cited 7 July 2024.
McGowan J, Sampson M, Salzwedel D, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clinl Epidemiol. 2016;75:40–6.
Jünger S, Payne SA, Brine J, Radbruch L, Brearley SG. Guidance on conducting and REporting DElphi Studies (CREDES) in palliative care: Recommendations based on a methodological systematic review. Palliat Med. 2017;31(8):684–706.
Khodyakov D, Grant S, Kroger J, Bauman M. RAND Methodological Guidance for Conducting and Critically Appraising Delphi Panels. [Internet] Santa Monica, CA: RAND Corporation, 2023. Available from: https://www.rand.org/pubs/tools/TLA3082-1.html. Cited 5 July 2024.
Opinio (version 7.5). Oslo, Norway: ObjectPlanet Inc.; Copyright 1998–2024 Available from: https://objectplanet.com/opinio/.
Schütze A, Benöhr P, Haubitz M, Radziwill R, Hohmann C. Development of a list with renally relevant drugs as a tool to increase medicines optimisation in patients with chronic kidney disease. Eur J Hosp Pharm. 2023;30(1):46–52.
Hamzaei Z, Houlind MB, Kjeldsen LJ, Christensen LWS, Walls AB, Aharaz A, Olesen C, Coric F, Revell JHP, Ravn-Nielsen LV, Andersen TRH, Hedegaard U. Inappropriate prescribing in patients with kidney disease: A rapid review of prevalence, associated clinical outcomes and impact of interventions. Basic Clin Pharmacol Toxicol. 2024;134(4):439–59.
Escribá-Martí G, Cámara-Ramos I, Climent-Catalá MT, Escudero-Quesada V, Salar-Ibáñez L. Pharmaceutical care program for patients with chronic kidney disease in the community pharmacy: Detection of nephrotoxic drugs and dose adjustment Viability Study. PLoS One. 2022;17(12):e0278648.
Mongaret C, Aubert L, Lestrille A, Albaut V, Kreit P, Herlem E, Noel N, Touré F, Lallier F, Slimano F, MIRPhO Investigators Study T. The role of community pharmacists in the detection of clinically relevant drug-related problems in chronic kidney disease patients. Pharmacy (Basel). 2020;8(2):89.
Canadian Pharmacists Association. Pharmacist’s Scope of Practice in Canada. Published October 2023. Available from: https://www.pharmacists.ca/advocacy/scope-of-practice/. Accessed 15 Aug 2024.
- The Renal Warrior Project. Join Now
- Source: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-024-03829-y
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://renal.platohealth.ai/medications-for-community-pharmacists-to-dose-adjust-or-avoid-to-enhance-prescribing-safety-in-individuals-with-advanced-chronic-kidney-disease-a-scoping-review-and-modified-delphi-bmc-nephrology/